摘要
角膜缘干细胞缺乏(LSCD)可以与许多眼表及全身免疫系统疾病相关,已成为角膜盲的重要原因之一。过去对LSCD的诊断主要基于病史及临床症状,然而LSCD的临床表现缺乏特异性,甚至根据部分临床表现不足以诊断LSCD。近年来,新开发的眼部成像技术以及分子生物标志物的应用使LSCD的诊断进入了新时代。随着人们对角膜缘上皮干细胞作用的进一步认识以及组织工程领域技术的发展,LSCD的手术治疗方式有了较大进展,在我国角膜供体材料匮乏的情况下,为患者带来了新希望。
Limbal stem cell deficiency(LSCD)can be associated with many ocular surface and systemic immune system diseases and has become one of the important causes of corneal blindness.In the past,the diagnosis of LSCD has been made mainly based on medical history and clinical signs,which often are not specific.And according to some clinical manifestations,it′s even not enough to diagnose LSCD.In recent years,the application of the newly developed eye imaging technology and the molecular biomarkers have brought the diagnosis of LSCD into a new era.With the further understanding of the role of limbal epithelial stem cells and the development of tissue engineering techniques,the surgical treatment of LSCD has made great progress,which brings new hope for the patients in the absence of corneal donor materials in China.
作者
潘玉苗
杨燕宁
PAN Yumiao;YANG Yanning(Eye Center,Renmin Hospital of Wuhan University,Wuhan 430060,China)
出处
《医学综述》
2020年第23期4672-4677,共6页
Medical Recapitulate
基金
国家自然科学基金(81770899)。
关键词
角膜缘干细胞缺乏
移植
手术治疗
Limbal stem cell deficiency
Transplantation
Surgical treatment